Klin Farmakol Farm. 2019;33(3):20-24 | DOI: 10.36290/far.2019.019

Immune-related adverse events associated with immune check-point inhibitors

David Suchý

Oddělení klinické farmakologie, Fakultní nemocnice v Plzni

Immune checkpoint inhibitors(ICIs) are monoclonal antibodies with immunomodulatory properties, that blocks inhibitors of T cells activation and function. ICIs are approved for treatment of select cancers and have shown survival benefit in some patients for more than 5 years. These therapies upregulate the immune system to enhance antitumor responses. As a consequence, they can cause immune-related adverse events (irAE) that are frequent, can affect one or more organs, can be serious, and on occasion lifethreatening. The management of these adverse events is complex, and requires a multidisciplinary approach to ensure prompt diagnosis and optimal management of these complications. This article rewiews shortly the clinical manifestations and managment of the most common and severe adverse events.

Keywords: immune checkpoint inhibitors, immune-related adverse events, management

Published: October 28, 2019  Show citation